Pharmaceutical Interests Versus AIDS In Africa (p 89)July 09, 2003The appointment of Randall Tobias as the US Government's global AIDS co-ordinator is analysed in this week's editorial. Tobias will head up a $15 billion programme to tackle AIDS in the African and Caribbean countries most devastated by the pandemic, although sceptics point out that his lack of knowledge about Africa and his pharmaceutical industry connections could weaken his appointment to this crucial role in global health. The editorial comments: 'Rapid appointment of a team behind him with proven African public-health and HIV experience would help him gain credibility in his new role, as would announcement of a detailed plan of how the Bush AIDS initiative will work with the Global Fund to Fight AIDS, Tuberculosis and Malaria. His connections with the pharmaceutical industry have led to concerns about whether Tobias is committed to providing access to low-cost generic AIDS drugs, or whether he will purchase patented versions so protecting the interests of US drug companies. Tobias needs quickly, and publicly, to support purchasing of low-cost generics to provide ammunition against those who charge that he is no more than a stooge of the drug industry. He could even go as far as to counter current US opposition to full implementation of the Doha Declaration of 2001.' Recognising the significance of Tobias' appointment, the editorial concludes: 'Bush and Tobias together could, with the backing of Congress, change the nature of HIV/AIDS in Africa. If all Tobias' targets are met, which is likely only if the full US$15 billion is appropriated by Congress, then he will have proven himself a worthy Global AIDS Coordinator. Tobias' task then, surely, as befits his job title, will be to combat the emerging HIV pandemic in Asia.' | |||||||||||||||||||||
|
Related AIDS Current Events and AIDS News Articles Study sheds light on causes of HIV dementia A new study led by researchers at Albert Einstein College of Medicine of Yeshiva University has clarified how two major variants of HIV differ in their ability to cause neurologic complications. New HIV film tackles stigma faced by teachers in Africa Addressing the discrimination against HIV-positive teachers in Africa is a key aim of a new documentary and accompanying book being launched in Senegal today by the Partnership for Child Development based at Imperial College London. Selenium may slow march of AIDS Increasing the production of naturally occurring proteins that contain selenium in human blood cells slows down multiplication of the AIDS virus, according to biochemists. Claudin 11 stops the leaks in neuronal myelin sheaths Devaux and Gow demonstrate how a tight junction protein called claudin 11 makes the neuronal myelin sheath a snug fit. ACP recommends routine HIV screening for all patients On World AIDS Day, the American College of Physicians (ACP) is giving doctors a call-to-action to routinely encourage HIV screening to all of their patients older than 13 years. This new practice guideline appears on the Annals of Internal Medicine Web site at www.annals.org. Scientists build 'roach motel' for nasty bugs of the bacterial variety The vacancy sign is on, but the lowlifes who check in never check out. Scientists at the University of Florida and the University of New Mexico have created tiny microscopic spheres that trap and kill harmful bacteria in a manner the scientists liken to "roach motels" snaring and killing cockroaches. Study of ancient and modern plagues finds common features In 430 B.C., a new and deadly disease-its cause remains a mystery-swept into Athens. The walled Greek city-state was teeming with citizens, soldiers and refugees of the war then raging between Athens and Sparta. Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. Landmark study defines benefits of early HIV testing and treatment for infected infants Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine. More AIDS Current Events and AIDS News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||